Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1456) (CBMAB-H2419-FY)

Basic Information
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:23184984, PubMed:29262349, PubMed:19304799).
In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247).
Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:23184984, PubMed:29262349, PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:27859042).
Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:23184984, PubMed:29262349, PubMed:16366734, PubMed:19304799).
Through interaction with KIR2DL4 receptor on decidual macrophages induces proinflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799).
Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042).
May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251).
Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251).
May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007).
Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620).
Isoform 2:
Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782).
Isoform 3:
Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782).
Isoform 4:
Likely does not bind B2M and presents peptides. Negatively regulates NK cell- and CD8+ T cell-mediated cytotoxicity (PubMed:11290782).
Isoform 5:
Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface (PubMed:23184984, PubMed:29262349, PubMed:19304799).
In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247).
Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal-fetal tolerance (PubMed:23184984, PubMed:29262349, PubMed:16366734, PubMed:19304799, PubMed:20448110).
Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal growth in early pregnancy (PubMed:23184984, PubMed:29262349, PubMed:16366734, PubMed:19304799).
Through interaction with KIR2DL4 receptor on decidual macrophages induces proinflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799).
Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110).
Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251).
Isoform 6:
Likely does not bind B2M and presents peptides.
Isoform 7:
Likely does not bind B2M and presents peptides.
Antigen processing and presentation of peptide antigen via MHC class I Source: UniProtKB-KW
Cellular defense response Source: ProtInc
Immune response-inhibiting cell surface receptor signaling pathway Source: BHF-UCL
Negative regulation of angiogenesis Source: UniProtKB
Negative regulation of dendritic cell differentiation Source: BHF-UCL
Negative regulation of G0 to G1 transition Source: UniProtKB
Negative regulation of immune response Source: UniProtKB
Negative regulation of natural killer cell mediated cytotoxicity Source: UniProtKB
Negative regulation of protein kinase B signaling Source: UniProtKB
Negative regulation of T cell mediated cytotoxicity Source: UniProtKB
Negative regulation of T cell proliferation Source: BHF-UCL
Peripheral B cell tolerance induction Source: UniProtKB
Positive regulation of cellular senescence Source: UniProtKB
Positive regulation of endothelial cell apoptotic process Source: UniProtKB
Positive regulation of interleukin-12 production Source: BHF-UCL
Positive regulation of macrophage cytokine production Source: UniProtKB
Positive regulation of natural killer cell cytokine production Source: UniProtKB
Positive regulation of regulatory T cell differentiation Source: BHF-UCL
Positive regulation of T cell tolerance induction Source: BHF-UCL
Positive regulation of tolerance induction Source: UniProtKB
Protection from natural killer cell mediated cytotoxicity Source: UniProtKB
Protein homotrimerization Source: UniProtKB
Chain Soluble HLA class I histocompatibility antigen, alpha chain G: Secreted
Isoform 2: Cell membrane
Isoform 3: Cell membrane
Isoform 4: Cell membrane
Isoform 5: Secreted; Early endosome
Isoform 6: Secreted
Isoform 7: Secreted; Filopodium membrane. HLA-G trogocytosis from extravillous trophoblast's filopodia occurs in the majority of decidual NK cells.
Helical: 309-332
Cytoplasmic: 333-338
Soluble HLA class I histocompatibility antigen, alpha chain G:
Produced by proteolytic cleavage at the cell surface (shedding) by matrix metalloproteinase MMP2.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Related Products
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1459) (CAT#: CBMAB-H0707-FY)
Mouse Anti-HLA-G Monoclonal Antibody (CBFYH-3152) (CAT#: CBMAB-H2412-FY)
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1462) (CAT#: CBMAB-H0771-FY)
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1470) (CAT#: CBMAB-H2424-FY)
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1458) (CAT#: CBMAB-H0706-FY)
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1447) (CAT#: CBMAB-H2415-FY)
Mouse Anti-HLA-G Monoclonal Antibody (CBFYH-3150) (CAT#: CBMAB-H0251-FY)
Mouse Anti-HLA-G Monoclonal Antibody (CBFYH-3146) (CAT#: CBMAB-H0247-FY)
Mouse Anti-HLA-G Recombinant Antibody (CBFYH-1466) (CAT#: CBMAB-H0767-FY)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
